Strands

Premium

Cenix Begins Target Validation Work for AstraZeneca

Cenix BioScience announced this week that it has begun a second research project under an existing arrangement with AstraZeneca.

According to Cenix, the new project will focus on cell-based studies to advance the validation of novel oncology-target candidates recently identified by the company in RNAi screens conducted for AstraZeneca.

Specific terms of the new agreement were not disclosed.


RXi Q4 Losses Rise on Higher R&D Spending, Delivery Technology License

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.